Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833569 | 0.88 | CDK2 (0.40) | ALBCDK2HIF1APPARGLRRK2 | |
| SCHEMBL6833108 | 0.87 | HIF1A (0.39) | ALBCDK2HIF1APPARG | |
| SCHEMBL6833068 | 0.83 | ALB (0.39) | ALBCDK2HIF1APPARG | |
| SCHEMBL6830652 | 0.83 | ALB (0.44) | ALBCDK2HIF1APPARG | |
| SCHEMBL6835869 | 0.83 | HIF1A (0.41) | ALBHIF1APPARGLRRK2 | |
| SCHEMBL6834155 | 0.81 | F2 (0.50) | ALBHIF1ALRRK2 | |
| SCHEMBL6834064 | 0.80 | ALB (0.42) | ALBHIF1ALRRK2 | |
| SCHEMBL6833806 | 0.80 | KDM4C (0.45) | ALBHIF1A | |
| SCHEMBL6834208 | 0.80 | LMNA (0.49) | CDK2HIF1AEGLN2PPARGKDM4E | |
| SCHEMBL6814370 | 0.80 | ALB (0.42) | ALBCDK2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALB 1417/4885CDK2 4509/4885HIF1A 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.